Pharmaceutical

CatalYm secures $150m to advance GDF-15-targeting immune modulator   

The new funding is set to fund the expansion of the company’s Phase IIb studies into visugromab in combination with checkpoint inhibitors.

Jul 18, 2024 - 04:00
CatalYm secures $150m to advance GDF-15-targeting immune modulator   
The new funding is set to fund the expansion of the company’s Phase IIb studies into visugromab in combination with checkpoint inhibitors.
Read the original article

Tags:

Previous Article

AbbVie’s Humira loss of exclusivity has been a missed opportunity for competitors

Next Article

Cardurion closes $260m in Series B to develop cardiovascular pipeline

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: STAT-Harris Poll: Most Americans are worried about RSV

STAT+: STAT-Harris Poll: Most Americans are worried abo...

Apr 19, 2023

Grit Biotechnology secures funds for development of pipeline programmes

Grit Biotechnology secures funds for development of pip...

Sep 11, 2023

Opinion: How the twin crises of climate change and poor public housing are harming people’s health

Opinion: How the twin crises of climate change and poor...

Aug 29, 2023